Literature DB >> 2394830

Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.

L De Marco1, M Mazzucato, D De Roia, A Casonato, A B Federici, A Girolami, Z M Ruggeri.   

Abstract

We have studied the interaction of the congenitally abnormal type IIA and IIB von Willebrand factor (vWF) molecules, both lacking the larger multimeric forms, with the two vWF binding sites on platelets, the glycoprotein (GP) Ib-IX and GP IIb-IIIa complexes. Variant as well as normal (N) vWF were purified from plasma. Estimates for binding of subunit molecules per platelet at saturation (Bmax) and dissociation constant in moles/liter (Kd), respectively, were obtained from binding isotherms of 125I-labeled vWF, with the following results. In the presence of ristocetin (binding to GP Ib-IX): N, 25,693 and 0.5 x 10(-8); IIA, both parameters not measurable; IIB, 17,708 and 0.87 x 10(-8). After thrombin stimulation (binding to GP IIb-IIIa): N, 17,059 and 1.12 x 10(-8); IIA, 23,751 and 4.87 x 10(-8); IIB, 19,890 and 2.52 x 10(-8). Distinct experiments based on measuring the ability of the variant species (from the same patients and one additional IIB patient) to inhibit the binding of normal 125I-vWF to platelets gave results in agreement with those reported above. Other studies showed that only IIB vWF bound to platelets in the absence of any mediating substance (Kd = 5.21 x 10(-8) mol/liter and Bmax = 9,599 subunits per platelet) and induced aggregation at a concentration of 10 micrograms/ml (3.6 x 10(-8) M). Thus, IIB vWF binds to GP Ib-IX with high affinity and induces platelet aggregation, whether with or without ristocetin, in spite of the absence of larger multimers. In contrast, the binding of IIA vWF to GP Ib-IX occurs with very decreased affinity, and this defective function may result from specific structural abnormalities rather than just being a reflection of the absence of larger multimeric forms. Both IIA and IIB vWF exhibit decreased affinity for GP IIb-IIIa. In this case, the extent of the defect correlates with the absence of larger multimers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394830      PMCID: PMC296793          DOI: 10.1172/JCI114775

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

2.  Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets.

Authors:  H R Gralnick; S B Williams; D K Morisato
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

3.  Type IIB von Willebrand's disease: differential clearance of endogenous versus transfused large multimer von willebrand factor.

Authors:  Z M Ruggeri; R Lombardi; L Gatti; R Bader; C Valsecchi; T S Zimmerman
Journal:  Blood       Date:  1982-12       Impact factor: 22.113

4.  Mechanism of binding of multivalent immune complexes to Fc receptors. 1. Equilibrium binding.

Authors:  S K Dower; C DeLisi; J A Titus; D M Segal
Journal:  Biochemistry       Date:  1981-10-27       Impact factor: 3.162

5.  Platelets have more than one binding site for von Willebrand factor.

Authors:  Z M Ruggeri; L De Marco; L Gatti; R Bader; R R Montgomery
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.

Authors:  L De Marco; A Girolami; T S Zimmerman; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.

Authors:  L De Marco; A Girolami; S Russell; Z M Ruggeri
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

9.  Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody.

Authors:  V T Lombardo; E Hodson; J R Roberts; T J Kunicki; T S Zimmerman; Z M Ruggeri
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746.

Authors:  S Berliner; K Niiya; J R Roberts; R A Houghten; Z M Ruggeri
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

View more
  9 in total

1.  Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; D Lillicrap
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

2.  Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Authors:  Caterina Casari; David S Paul; Sophie Susen; Cécile Lavenu-Bombled; Annie Harroche; Raymond Piatt; Kathryn O Poe; Robert H Lee; Marijke Bryckaert; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Wolfgang Bergmeier
Journal:  Blood Adv       Date:  2018-06-26

3.  Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.

Authors:  K A Cooney; S E Lyons; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.

Authors:  J Ware; J A Dent; H Azuma; M Sugimoto; P A Kyrle; A Yoshioka; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

6.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.

Authors:  A Casonato; E Pontara; A Bertomoro; D Dannhauser; S Secchiero; M Zaninotto; A Girolami
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

9.  O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

Authors:  J A Carew; S M Quinn; J H Stoddart; D C Lynch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.